

14 May 2025

Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")

**Timing of AGM
and
Change of Record Date for Final Dividend**

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that, as a consequence of unforeseen changes within the audit team at Deloitte LLP, and the associated delay in expected signing date of the Annual Report and Accounts, the Company now expects its Annual General Meeting ("AGM") to be held on 30 June 2025. Subsequently, following the announcement of our FY24 Unaudited Preliminary Results (issued at 07:00 on 19 March 2025 under RNS 2726B), we are changing the record date for our proposed final dividend of 1.83p per share to 20 June 2025.

As a result of this change, and subject to approval by shareholders at the forthcoming AGM, the proposed final dividend will be paid on 17 July 2025 to shareholders on the register at the close of business on 20 June 2025.

- End -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Michael King, Investor Relations

Tel: +44 (0) 1606 545508

ICR Healthcare
Mary-Jane Elliott / Lucy Featherstone

Tel: +44 (0) 20 3709 5700
AMS@icrhealthcare.com

Investec Bank PLC (NOMAD & Broker)
Gary Clarence / David Anderson

Tel: +44 (0) 20 7597 5970

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexion, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,600 employees. For more information, please see www.admedsol.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDEADSLFSXSEFA